Salim Syed
Stock Analyst at Mizuho
(3.08)
# 2,444
Out of 5,182 analysts
86
Total ratings
45.71%
Success rate
1.62%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Salim Syed
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| BBIO BridgeBio Pharma | Reiterates: Outperform | $106 | $73.44 | +44.34% | 9 | Apr 28, 2026 | |
| AUTL Autolus Therapeutics | Maintains: Outperform | $12 → $10 | $1.46 | +584.93% | 1 | Mar 31, 2026 | |
| SNDX Syndax Pharmaceuticals | Maintains: Outperform | $45 → $43 | $21.11 | +103.69% | 1 | Mar 31, 2026 | |
| NKTX Nkarta | Maintains: Outperform | $14 → $12 | $2.81 | +327.05% | 9 | Mar 31, 2026 | |
| ELVN Enliven Therapeutics | Maintains: Outperform | $41 → $45 | $43.53 | +3.38% | 2 | Mar 25, 2026 | |
| WVE Wave Life Sciences | Maintains: Outperform | $22 → $27 | $7.40 | +264.86% | 6 | Mar 25, 2026 | |
| CYTK Cytokinetics | Maintains: Outperform | $84 → $100 | $62.75 | +59.36% | 8 | Mar 18, 2026 | |
| MAZE Maze Therapeutics | Initiates: Outperform | $97 | $26.39 | +267.63% | 1 | Mar 10, 2026 | |
| INCY Incyte | Upgrades: Outperform | $90 → $121 | $96.58 | +25.28% | 1 | Dec 8, 2025 | |
| ASMB Assembly Biosciences | Maintains: Outperform | $29 → $40 | $27.60 | +44.93% | 2 | Nov 20, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $207 → $169 | $182.80 | -7.55% | 16 | May 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $235 → $280 | $342.82 | -18.32% | 8 | May 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $100 → $117 | $129.30 | -9.51% | 7 | May 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $113 → $163 | $60.00 | +171.67% | 3 | Sep 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $25 → $18 | $4.93 | +265.11% | 4 | Aug 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $82 → $99 | $51.08 | +93.81% | 3 | Mar 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $28 → $21 | $1.85 | +1,038.21% | 5 | Nov 16, 2022 |
BridgeBio Pharma
Apr 28, 2026
Reiterates: Outperform
Price Target: $106
Current: $73.44
Upside: +44.34%
Autolus Therapeutics
Mar 31, 2026
Maintains: Outperform
Price Target: $12 → $10
Current: $1.46
Upside: +584.93%
Syndax Pharmaceuticals
Mar 31, 2026
Maintains: Outperform
Price Target: $45 → $43
Current: $21.11
Upside: +103.69%
Nkarta
Mar 31, 2026
Maintains: Outperform
Price Target: $14 → $12
Current: $2.81
Upside: +327.05%
Enliven Therapeutics
Mar 25, 2026
Maintains: Outperform
Price Target: $41 → $45
Current: $43.53
Upside: +3.38%
Wave Life Sciences
Mar 25, 2026
Maintains: Outperform
Price Target: $22 → $27
Current: $7.40
Upside: +264.86%
Cytokinetics
Mar 18, 2026
Maintains: Outperform
Price Target: $84 → $100
Current: $62.75
Upside: +59.36%
Maze Therapeutics
Mar 10, 2026
Initiates: Outperform
Price Target: $97
Current: $26.39
Upside: +267.63%
Incyte
Dec 8, 2025
Upgrades: Outperform
Price Target: $90 → $121
Current: $96.58
Upside: +25.28%
Assembly Biosciences
Nov 20, 2025
Maintains: Outperform
Price Target: $29 → $40
Current: $27.60
Upside: +44.93%
May 7, 2025
Maintains: Outperform
Price Target: $207 → $169
Current: $182.80
Upside: -7.55%
May 7, 2025
Maintains: Neutral
Price Target: $235 → $280
Current: $342.82
Upside: -18.32%
May 5, 2025
Maintains: Outperform
Price Target: $100 → $117
Current: $129.30
Upside: -9.51%
Sep 10, 2024
Maintains: Outperform
Price Target: $113 → $163
Current: $60.00
Upside: +171.67%
Aug 16, 2024
Upgrades: Outperform
Price Target: $25 → $18
Current: $4.93
Upside: +265.11%
Mar 6, 2024
Maintains: Buy
Price Target: $82 → $99
Current: $51.08
Upside: +93.81%
Nov 16, 2022
Maintains: Buy
Price Target: $28 → $21
Current: $1.85
Upside: +1,038.21%